A Machine Learning Model Based on Counterfactual Theory for Treatment Decision of Hepatocellular Carcinoma Patients

被引:1
作者
Wei, Xiaoqin [1 ]
Wang, Fang [2 ]
Liu, Ying [3 ]
Li, Zeyong [4 ]
Xue, Zhong [2 ]
Tang, Mingyue [5 ]
Chen, Xiaowen [1 ]
机构
[1] North Sichuan Med Coll, Sch Med Imaging, 234 Fujiang Rd, Nanchong 637001, Sichuan, Peoples R China
[2] Shanghai United Imaging Intelligence Co Ltd, Dept Res & Dev, Shanghai, Peoples R China
[3] Chengdu Med Coll, Affiliated Hosp 1, Dept Orthoped, Chengdu, Sichuan, Peoples R China
[4] Chongqing Med Univ, Dept Radiol, Bishan Hosp, Chongqing, Peoples R China
[5] North Sichuan Med Coll, Sch Basic Med, Dept Phys, Nanchong, Peoples R China
关键词
radiomics; hepatocellular carcinoma; prognosis; hepatectomy; TRANSARTERIAL CHEMOEMBOLIZATION; HEPATIC RESECTION; PARTIAL-HEPATECTOMY; LIVER RESECTION; SURVIVAL;
D O I
10.2147/JHC.S470550
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To predict the efficacy of patients treated with hepatectomy and transarterial chemoembolization (TACE) based on machine learning models using clinical and radiomics features. Patients and Methods: Patients with HCC whose first treatment was hepatectomy or TACE from June 2016 to July 2021 were collected in the retrospective cohort study. To ensure a causal effect of treatment effect and treatment modality, perfectly matched patients were obtained according to the principle of propensity score matching and used as an independent test cohort. Inverse probability of treatment weighting was used to control bias for unmatched patients, and the weighted results were used as the training cohort. Clinical characteristics were selected by univariate and multivariate analysis of cox proportional hazards regression, and radiomics features were selected using correlation analysis and random survival forest. The machine learning models (Death hepatectomy and DeathTACE) TACE ) were constructed to predict the probability of patient death after treatment (hepatectomy and TACE) by combining clinical and radiomics features, and an optimal treatment regimen was recommended. In addition, a prognostic model was constructed to predict the survival time of all patients. Results: A total of 418 patients with HCC who received either hepatectomy (n=267, mean age, 58 years +/- 11 [standard deviation]; 228 men) or TACE (n=151, mean age, 59 years +/- 13 [standard deviation]; 127 men) were recruited. After constructing the machine learning models Death hepatectomy and DeathTACE, TACE , patients were divided into the hepatectomy-preferred and TACE-preferred groups. In the hepatectomy-preferred group, hepatectomy had a significantly prolonged survival time than TACE (training cohort: P < 0.001; testing cohort: P < 0.001), and vise versa for the TACE-preferred group. In addition, the prognostic model yielded high predictive capability for overall survival. Conclusion: The machine learning models could predict the outcomes difference between hepatectomy and TACE, and prognostic models could predict the overall survival for HCC patients.
引用
收藏
页码:1675 / 1687
页数:13
相关论文
共 50 条
  • [21] Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
    Gross, Moritz
    Haider, Stefan P.
    Ze'evi, Tal
    Huber, Steffen
    Arora, Sandeep
    Kucukkaya, Ahmet S.
    Iseke, Simon
    Gebauer, Bernhard
    Fleckenstein, Florian
    Dewey, Marc
    Jaffe, Ariel
    Strazzabosco, Mario
    Chapiro, Julius
    Onofrey, John A.
    [J]. EUROPEAN RADIOLOGY, 2024, 34 (10) : 6940 - 6952
  • [22] Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery
    Shao, Guanming
    Ma, Yonghui
    Qu, Chao
    Gao, Ruiqian
    Zhu, Chengzhan
    Qu, Linlin
    Liu, Kui
    Li, Na
    Sun, Peng
    Cao, Jingyu
    [J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 679 - 691
  • [23] Prediction model for hepatocellular carcinoma recurrence after hepatectomy: Machine learning-based development and interpretation study
    Liu, Rongqiang
    Wu, Shinan
    Yu, Hao yuan
    Zeng, Kaining
    Liang, Zhixing
    Li, Siqi
    Hu, Yongwei
    Yang, Yang
    Ye, Linsen
    [J]. HELIYON, 2023, 9 (11)
  • [24] Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma
    Dong, Bingtian
    Zhang, Hua
    Duan, Yayang
    Yao, Senbang
    Chen, Yongjian
    Zhang, Chaoxue
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [25] Predictive machine learning model for microvascular invasion identification in hepatocellular carcinoma based on the LI-RADS system
    Yang, Xue
    Shao, Guoqing
    Liu, Jiaojiao
    Liu, Bin
    Cai, Chao
    Zeng, Daobing
    Li, Hongjun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Identification of potential biomarkers for hepatocellular carcinoma based on machine learning and bioinformatics analysis
    Chen, Chen
    Peng, Rui
    Jin, Shengjie
    Tang, Yuhong
    Liu, Huanxiang
    Tu, Daoyuan
    Su, Bingbing
    Wang, Shunyi
    Jiang, Guoqing
    Cao, Jun
    Zhang, Chi
    Bai, Dousheng
    [J]. DISCOVER ONCOLOGY, 2024, 15 (01)
  • [27] Expert Perspectives on Evidence-Based Treatment Planning for Patients With Hepatocellular Carcinoma
    Marrero, Jorge
    Maluccio, Mary A.
    McCurdy, Heather
    Abou-Alfa, Ghassan K.
    [J]. CANCER CONTROL, 2014, 21 (02) : 5 - 16
  • [28] An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
    Zhang, Guizhen
    Zhu, Weiwei
    Wang, Yun
    Cui, Guangying
    Zhang, Yize
    Yu, Zujiang
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [29] Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study
    Lu, Ningning
    Sheng, Shugui
    Xiong, Yiqi
    Zhao, Chuanren
    Qiao, Wenying
    Ding, Xiaoyan
    Chen, Jinglong
    Zhang, Yonghong
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma
    Ma, Ya
    Gong, Yue
    Qiu, Qingtao
    Ma, Changsheng
    Yu, Shuang
    [J]. BMC CANCER, 2024, 24 (01)